Page 1 | Search Results | Journal of Human Immunity

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis

Jennifer Jess, Bethany Verkamp, Michael Jordan

J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.195.

https://doi.org/10.70962/CIS2025abstract.195

Published: 25 April 2025

View articletitled, Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis

Journal Articles

T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis

Nicole Wozny, Hana Niebur, Michael Jordan

J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.200.

https://doi.org/10.70962/CIS2025abstract.200

Published: 25 April 2025

View articletitled, T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis

Journal Articles

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure

Rebecca Marsh, Ruby Khoury, Kana Mizuno, Anhar Hosawi, Caitlin Cottrell, Evelyn Nguyen, Brady Landon, Sharat Chandra, Michael Jordan, Ashish Kumar, Jack Bleesing, Stella Davies, Carol Moore, Parinda Mehta

J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.97.

https://doi.org/10.70962/CIS2025abstract.97

Published: 25 April 2025

View articletitled, Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure

Journal Articles

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity

Ruby Khoury, Michael Jordan, Jack Bleesing, Ashish Kumar, Blachy Davila Saldana, Bethany Verkamp, Stella Davies, Rebecca Marsh, Sharat Chandra

J Hum Immun (2025) 1 (CIS2025): CIS2025abstract.61.

https://doi.org/10.70962/CIS2025abstract.61

Published: 25 April 2025

View articletitled, Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity

Update search

NARROW

Format

Journal

Article Type

Date

Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis

T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity

Email alerts

Update search

Vitamin D Deficiency Is Prevalent and Resistant to Correction in Patients with Hemophagocytic Lymphohistiocytosis

T Cell Tropic Epstein Barr Virus in a Patient with Hemophagocytic Lymphohistiocytosis

Precision Alemtuzumab Dosing Results in Day 0 Target Range Achievement in 80% of IEI Patients and Minimizes Risks of GVHD, Clinically Significant Mixed Chimerism, and Secondary Graft Failure

Addition of Thiotepa to Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Reduces Secondary Graft Failure in Allogeneic HSCT for Inborn Errors of Immunity

Email alerts

This Feature Is Available To Subscribers Only